Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
BASEL, Switzerland, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women ' s health and prostate cancer, today announced that the Phase 3 HERO...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Oral Cancer | Pharmaceuticals | Prostate Cancer | Study | Switzerland Health | Women